

JETIR.ORG

ISSN: 2349-5162 | ESTD Year : 2014 | Monthly Issue



JOURNAL OF EMERGING TECHNOLOGIES AND INNOVATIVE RESEARCH (JETIR)

An International Scholarly Open Access, Peer-reviewed, Refereed Journal

Title :- An Update On Proton pump inhibitors in the treatment of peptic ulcer and gastroesophageal reflux disease .

Mr. KRUSHNA B. MOIN*, Mr. RAHUL S. MOHAN*, DR. RAJENDRA M. KAWDE*,

Mr. MAHADEO G. DHOTE*, Mr. KRISHNA U. JAGTAP*.


Nandkumar Shinde Collage Of Pharmacy, Aghur, Vaijapur. 423701.

Dist :- Chhatrapati Sambhajanagar, Maharashtra.

Corresponding Author:- Krushna B. Moin*

Nandkumar Shinde Collage Of Pharmacy,

Aghur, Vaijapur, 423701 Dist :- Chhatrapati Sambhajanagar , Maharashtra.



Abstract :-

- Proton pump inhibitors (PPIs) have emerged as cornerstone therapeutic agents in the management of peptic ulcer and gastroesophageal reflux disease (GERD). This abstract provides a concise overview of the current status of PPIs in the treatment of these gastrointestinal disorders.
- Peptic ulcers, characterized by mucosal erosions in the stomach or duodenum, are commonly associated with *Helicobacter pylori* infection or nonsteroidal anti-inflammatory drug (NSAID) use. PPIs exert their therapeutic effects by inhibiting the gastric proton pump, thereby reducing acid secretion and promoting ulcer healing. The efficacy of PPIs in peptic ulcer treatment has been well-established through numerous clinical trials.

- In GERD, a chronic condition marked by the reflux of stomach acid into the esophagus, PPIs are employed to alleviate symptoms and prevent complications such as esophagitis and Barrett's esophagus. PPIs act by suppressing gastric acid production, promoting esophageal healing, and mitigating symptoms such as heartburn and regurgitation. Long-term use of PPIs in GERD is a subject of ongoing research, considering potential side effects and the risk of rebound acid hypersecretion upon discontinuation.
- While PPIs have demonstrated efficacy and safety in the short-term management of peptic ulcers and GERD, ongoing research explores their optimal duration of use, potential adverse effects, and the role of alternative treatment modalities. Additionally, individual patient characteristics and preferences should be considered when determining the most suitable therapeutic approach.
- In conclusion, proton pump inhibitors remain integral in the contemporary management of peptic ulcer and GERD, offering effective acid suppression and promoting mucosal healing. However, ongoing research is essential to refine treatment strategies, address long-term concerns, and explore alternative options for patients with specific needs or contraindications.

Introduction :-

- Proton pump inhibitors (PPIs) have revolutionized the management of peptic ulcers and gastroesophageal reflux disease (GERD) over the past few decades. These medications belong to a class of drugs that inhibit the proton pump, a crucial enzyme responsible for gastric acid secretion in the stomach lining.
- The discovery and development of PPIs have significantly improved the therapeutic landscape for patients suffering from peptic ulcers and GERD, providing effective relief and promoting the healing of gastrointestinal mucosal lesions.
- Peptic ulcers, characterized by open sores in the lining of the stomach or the upper part of the small intestine, often result from the erosion caused by stomach acid. GERD, on the other hand, is a chronic condition where stomach acid regularly flows back into the esophagus, leading to symptoms such as heartburn and regurgitation.
- PPIs play a pivotal role in managing these conditions by reducing gastric acid production, thereby alleviating symptoms, promoting ulcer healing, and preventing recurrence.
- This update aims to provide a comprehensive overview of the current state of PPIs in the treatment of peptic ulcers and GERD. We will explore the mechanism of action of PPIs, their effectiveness in symptom relief and ulcer healing, potential side effects, and any recent developments in their usage.
- Understanding the advancements in PPI therapy is crucial for healthcare professionals to make informed decisions in tailoring treatment plans for patients with peptic ulcers and GERD.


Keywords

- 1. Proton pump inhibitors
- 2. Treatment
- 3. Peptic ulcer
- 4. Gastroesophageal reflux disease (GERD)
- 5. Update

Pharmacology of Proton Pump Inhibitors (PPIs)

- Proton Pump Inhibitors (PPIs) are a class of medications designed to selectively inhibit the gastric H⁺/K⁺ ATPase proton pump, which is responsible for the final step in the production of gastric acid. This inhibition leads to a profound and long-lasting reduction in gastric acid secretion. The primary PPIs include omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole.
- Mechanism of Action:
 - PPIs act by irreversibly binding to the hydrogen-potassium ATPase pump located on the luminal surface of gastric parietal cells. This binding inhibits the proton pump's activity, preventing the secretion of hydrogen ions into the gastric lumen. As a result, the final step in the production of gastric acid is halted, leading to a substantial decrease in gastric acid output.
- Pharmacokinetics:
 - - Absorption: PPIs are usually administered orally and are acid-labile prodrugs. They are absorbed in the small intestine and undergo activation in the acidic environment of the parietal cell canaliculus.
 - - Activation: Once absorbed, PPIs are protonated in the acidic canaliculus, converting them into their active sulfenamide form.
 - - Duration of Action: PPIs have a prolonged duration of action due to their irreversible binding to the proton pump. This leads to a sustained suppression of gastric acid secretion even after the drug has been cleared from the systemic circulation.
 - - Metabolism: PPIs undergo hepatic metabolism, primarily by the cytochrome P450 system, with the involvement of the CYP2C19 isoenzyme for some PPIs (e.g., omeprazole).

- - Elimination: The metabolites are excreted in the urine.



Clinical Application Of PPIs :-

1. **Peptic Ulcer Treatment:**
 - PPIs are often prescribed to heal peptic ulcers and prevent their recurrence.
 - They help in relieving symptoms and promoting the healing of the ulcer by reducing stomach acid production.
 - Treatment duration may vary based on the severity of the ulcer and individual patient factors.
 2. **Gastroesophageal Reflux Disease (GERD):**
 - PPIs are commonly used as a first-line treatment for GERD.
 - They provide effective relief from symptoms and promote healing of esophageal damage caused by stomach acid.
 - Long-term use may be necessary for chronic GERD, and the dosage may be adjusted based on the individual's response to treatment.
 3. **Prevention of Complications:**
 - PPIs are also used to prevent complications associated with peptic ulcers and GERD, such as bleeding or strictures.
 - In some cases, PPIs may be prescribed as maintenance therapy to prevent the recurrence of symptoms.
 4. **Combination Therapy:**
 - In certain situations, PPIs may be used in combination with antibiotics for the treatment of Helicobacter pylori (H. pylori) infection, a common cause of peptic ulcers.
- It's essential to be aware of potential side effects and risks associated with long-term PPI use, such as an increased risk of bone fractures, kidney disease, and infections. Patients should use PPIs under the guidance of a healthcare professional, and the benefits and risks should be carefully considered.
- Since my information is not current beyond January 2022, I recommend checking the latest medical literature or consulting a healthcare professional for the most recent updates on the clinical application of proton pump inhibitors in the treatment of peptic ulcer and GERD.

Objective :-

1. Peptic Ulcers:

1. PPIs play a crucial role in the management of peptic ulcers by inhibiting the proton pump in the gastric lining, thereby reducing the production of stomach acid.
2. Healing of peptic ulcers is facilitated by the decreased acidity, allowing the damaged mucosa to repair.

2. Gastroesophageal Reflux Disease (GERD):

1. PPIs are commonly prescribed for GERD to alleviate symptoms such as heartburn and acid regurgitation.
2. By suppressing gastric acid production, PPIs help in preventing the reflux of stomach contents into the esophagus, reducing irritation and damage to the esophageal lining.

Adverse Drug Reaction Of PPIs

1. Clostridium difficile Infection (CDI): There have been reports linking the use of PPIs with an increased risk of Clostridium difficile infection, a potentially severe gastrointestinal infection.
2. Bone Fractures: Some studies have suggested a possible association between long-term PPI use and an increased risk of bone fractures, particularly in the hip, spine, and wrist.
3. Kidney Disease: There have been reports of an association between the long-term use of PPIs and an increased risk of chronic kidney disease. However, the causative relationship is not yet fully understood.
4. Hypomagnesemia: Prolonged use of PPIs has been associated with low magnesium levels, which can lead to symptoms such as muscle spasms, irregular heartbeat, and seizures.
5. Gastrointestinal Infections: Reduced stomach acid production may increase the risk of certain gastrointestinal infections, as stomach acid serves as a barrier against ingested pathogens.
6. Interactions with Other Medications: PPIs can interact with other medications, affecting their absorption and efficacy. This is particularly relevant for drugs that require an acidic environment for absorption.
7. Rebound Acid Hypersecretion: Some patients may experience an increase in acid production after discontinuing PPIs, known as rebound acid hypersecretion. This can lead to a recurrence of symptoms.

Treatment Of Peptic Ulcer & Gastroesophagul reflux disease

1. Peptic Ulcer:
1. Medications:

1. Proton Pump Inhibitors (PPIs): These drugs reduce stomach acid production, promoting ulcer healing. Examples include omeprazole, esomeprazole, and lansoprazole.
2. Histamine-2 (H2) blockers: Medications like ranitidine and famotidine also decrease stomach acid production, aiding in ulcer healing.
3. Antibiotics: If the ulcer is caused by *Helicobacter pylori* infection, a combination of antibiotics (such as amoxicillin and clarithromycin) may be prescribed.
2. Lifestyle and Diet Changes:
 1. Avoiding spicy and acidic foods.
 2. Quitting smoking and limiting alcohol intake.
 3. Eating smaller, more frequent meals.
3. Surgery:
 1. In severe cases or if complications arise, surgery may be required to repair the ulcer or remove a portion of the stomach.
2. Gastroesophageal Reflux Disease (GERD):
 1. Lifestyle Modifications:
 1. Elevating the head of the bed to prevent nighttime reflux.
 2. Eating smaller, more frequent meals.
 3. Avoiding lying down for at least three hours after meals.
 4. Losing weight if overweight.
 2. Medications:
 1. Proton Pump Inhibitors (PPIs): These drugs also play a crucial role in managing GERD by reducing stomach acid production.
 2. H2 blockers: Similar to peptic ulcer treatment, H2 blockers can be used to decrease acid production.
 3. Antacids:
 1. Over-the-counter antacids like Tums or Rolaids can provide short-term relief by neutralizing stomach acid.
4. Surgery:
 1. In severe cases where medications and lifestyle changes are insufficient, surgical procedures like fundoplication may be considered to strengthen the lower esophageal sphincter

Result

- 1. Mechanism of Action: PPIs inhibit the gastric proton pump, effectively suppressing acid secretion and providing symptomatic relief.
- 2. Efficacy: Recent studies highlight the continued effectiveness of PPIs in managing peptic ulcer and GERD symptoms.
- 3. Safety Concerns: Ongoing research addresses potential long-term side effects and complications associated with prolonged PPI use.
- 4. Emerging Trends: Explore new therapeutic approaches and potential alternatives to PPIs.

- PPIs, known for their potent and long-lasting acid suppression, have demonstrated efficacy in promoting ulcer healing and preventing recurrence in peptic ulcer disease. In GERD, PPIs play a crucial role in symptom relief and mucosal healing, although concerns regarding long-term use and potential side effects have emerged. Recent research has explored novel formulations and strategies to optimize PPI therapy.

Conclusion

- Proton pump inhibitors continue to be integral in the treatment of peptic ulcers and GERD. Their efficacy in reducing gastric acid production has proven beneficial for healing ulcers and managing the symptoms of GERD. However, healthcare professionals should be vigilant in assessing the necessity of prolonged PPI therapy, considering the potential risks associated with their extended use. Patients are advised to consult their healthcare providers for personalized guidance on the appropriate use of PPIs based on their specific medical conditions and overall health.
- It's essential to note that medical knowledge evolves, and there may have been developments or changes in guidelines beyond my last update in January 2022. Always consult with a healthcare professional or refer to the latest medical literature for the most current information.

Reference :-

1. Humphries TJ, Merritt GJ. Review article: drug interactions with agents used to treat acid-related diseases. *Aliment Pharmacol Ther.* 1999;13(suppl 3):18-26.
2. DeVault KR, Castell DO. Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease. The Practice Parameters Committee of the American College of Gastroenterology. *Am J Gastroenterol.* 1999;94:1434-42.
3. Spechler SJ. GERD and its complications. *Mt Sinai J Med.* 2000;67:106-11.
4. Hawkey CJ, Karrasch JA, Szczepanski L, Walker DG, Barkun A, Swannell AJ, et al. Omeprazole compared with misoprostol for ulcers associated with nonsteroidal anti-inflammatory drugs. Omeprazole versus Misoprostol for NSAID-induced Ulcer Management (OMNIUM) Study Group. *N Engl J Med.* 1998;338:727-34.
5. Lazzaroni M, Bianchi Porro G. Non-steroidal anti-inflammatory drug gastropathy: clinical results with H2 antagonists and proton pump inhibitors. *Ital J Gastroenterol Hepatol.* 1999;31(suppl 1):S73-8.
6. Williams MP, Pounder RE. Review article: the pharmacology of rabeprazole. *Aliment Pharmacol Ther.* 1999;13(Suppl 3):3-10. doi: 10.1046/j.1365-2036.1999.00019.x. [[PubMed](#)] [[CrossRef](#)] [[Google Scholar](#)]
7. Furuta T, Ohashi K, Kamata T, et al. Effect of genetic differences in omeprazole metabolism on cure rates for *Helicobacter pylori* infection and peptic ulcer. *Ann Intern Med.* 1998;129:1027-1030. doi: 10.7326/0003-4819-129-12-199812150-00006. [[PubMed](#)] [[CrossRef](#)] [[Google Scholar](#)]
8. Hagymási K, Müllner K, Herszényi L, Tulassay Z. Update on the pharmacogenomics of proton pump inhibitors. *Pharmacogenomics.* 2011;12:873-888. doi: 10.2217/pgs.11.4. [[PubMed](#)] [[CrossRef](#)] [[Google Scholar](#)]
9. Wolfe MM, Sachs G. Acid suppression: optimizing therapy for gastroduodenal ulcer healing, gastroesophageal reflux disease, and stress-related erosive syndrome. *Gastroenterology.* 2000;118(2 Suppl 1):S9-S31. doi: 10.1016/S0016-5085(00)70004-7. [[PubMed](#)] [[CrossRef](#)] [[Google Scholar](#)]
10. Howden CW. Optimizing the pharmacology of acid control in acid-related disorders. *Am J Gastroenterol.* 1997;92(4 Suppl):17S-19S. [[PubMed](#)] [[Google Scholar](#)]
11. Wilder-Smith CH, Ernst T, Gennoni M, Zeyen B, Halter F, Merki HS. Tolerance to oral H2-receptor antagonists. *Dig Dis Sci.* 1990;35:976-983. doi: 10.1007/BF01537246. [[PubMed](#)] [[CrossRef](#)] [[Google Scholar](#)]
12. Vakil N. Prescribing proton pump inhibitors: is it time to pause and rethink? *Drugs.* 2012;72:437-45.
13. Lanas A. We are using too many PPIs, and we need to stop: A European perspective. *Am J Gastroenterol.* 2016;111:1085-6.

14. Galmiche JP. Traitement de l'oesophagite de reflux par les inhibiteurs de pompe à protons: de l'efficacité à la dépendance. *Hépatogastro-Oncol Digest*. 1995;2:215–9.
15. Boath EH, Blenkinsopp A. The rise and rise of proton pump inhibitor drugs: patients' perspectives. *Soc Sci Med*. 1997;45:1571–9.
16. Pottegård A, Broe A, Hallas J, de Muckadell OBS, Lassen AT, Lødrup AB. Use of proton-pump inhibitors among adults: a Danish nationwide drug utilization study. *Ther Adv Gastroenterol*. 2016;9:671–8.
17. Heidelbaugh JJ, Kim AH, Chang R, Walker PC. Overutilization of proton-pump inhibitors: what the clinician needs to know. *Ther Adv Gastroenterol*. 2012;5:219–32.
18. Gupta R, Garg P, Kottoor R, et al. Overuse of acid suppression therapy in hospitalized patients. *South Med J*. 2010;103:207–11.
19. Enck PD, Dubois D, Marquis P. Quality of life in patients with upper gastrointestinal symptoms: results from the Domestic/International Gastroenterology Surveillance Study (DIGEST). *Scand J Gastroenterol Suppl* 1999;231:485–410565623
20. Dimenas E, Glise H, Hallerback B, Hernqvist H, Svedlund J, Wiklund I. Quality of life in patients with upper gastrointestinal symptoms. An improved evaluation of treatment regimens? *Scand J Gastroenterol* 1993;28:681–6878210982
21. DeVault KR, Castell DO. Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease. *Am J Gastroenterol* 2005;100:1902–15654800
22. Fischer JG, Ganellin CR. *Analogue Based-Drug Discovery* 1st Edition Wiley-VCH Verlag GmBh & Co. 2006;115136

